Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.

Trial Profile

Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Ibodutant (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Acronyms IRIS-2
  • Sponsors Menarini
  • Most Recent Events

    • 15 Apr 2016 Results published in the Gut
    • 21 May 2013 Results presented at Digestive Disease Week 2013.
    • 06 Oct 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top